CBD‐mediated regulation of heroin withdrawal‐induced behavioural and molecular changes in mice
- 11 February 2022
- journal article
- research article
- Published by Wiley in Addiction Biology
- Vol. 27 (2) , e13150
Abstract
Cannabidiol (CBD) may represent a promising therapeutic tool for treating opioid use disorder (OUD). This study was aimed to evaluate the effects of CBD on the behavioural and gene expression alterations induced by spontaneous heroin withdrawal. Thirty hours after cessation of 8‐day heroin treatment (5, 10, 20 and 40 mg·kg−1/12 h; s.c.), spontaneous heroin withdrawal was evaluated in CD1 male mice. The effects of CBD (5, 10 and 20 mg·kg−1; i.p.) on withdrawal‐related behaviour were evaluated by measuring anxiety‐like behaviour, motor activity and somatic signs. Furthermore, gene expression changes of mu‐opioid receptor (Oprm1), proopiomelanocortin (Pomc), cannabinoid CB1 (Cnr1) and CB2 (Cnr2) receptors in the nucleus accumbens (NAcc) and tyrosine hydroxylase (TH) and Pomc in the ventral tegmental area (VTA) were also evaluated by real‐time PCR. Anxiety‐like behaviour, motor activity and withdrawal‐related somatic signs were significantly increased in heroin‐treated mice compared to the control group. Interestingly, CBD treatment significantly reduced these behavioural impairments and normalized gene expression of Cnr1 and Pomc in the NAcc and TH in the VTA of mice exposed to spontaneous heroin withdrawal. Also, CBD induced an up‐regulation of Cnr2, whereas it did not change the increased gene expression of Oprm1 in the NAcc of abstinent animals. The results suggest that CBD alleviates spontaneous heroin withdrawal and normalizes the associated gene expression changes. Future studies are needed to determine the relevance of CBD as a potential therapeutic tool for the treatment of heroin withdrawal.Keywords
Funding Information
- Instituto de Salud Carlos III (Red de Trastornos Adictivos ‐ RD16/0017/0014)
- Ministerio de Sanidad, Consumo y Bienestar (Plan Nacional Sobre Drogas ‐ 2019I012)
This publication has 50 references indexed in Scilit:
- POMC overexpression in the ventral tegmental area ameliorates dietary obesityJournal of Endocrinology, 2011
- The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic–ischemic brain damage in mice is mediated by CB2 and adenosine receptorsNeurobiology of Disease, 2010
- Antidepressant‐like effects of cannabidiol in mice: possible involvement of 5‐HT1AreceptorsBritish Journal of Pharmacology, 2010
- Cannabidiol reduced the striatal atrophy caused 3‐nitropropionic acidin vivoby mechanisms independent of the activation of cannabinoid, vanilloid TRPV1and adenosine A2AreceptorsEuropean Journal of Neuroscience, 2007
- Cannabidiol displays unexpectedly high potency as an antagonist of CB1and CB2receptor agonistsin vitroBritish Journal of Pharmacology, 2007
- Mu opioid receptor and orexin/hypocretin mRNA levels in the lateral hypothalamus and striatum are enhanced by morphine withdrawalJournal of Endocrinology, 2006
- Regulation of Gene Expression by Chronic Morphine and Morphine Withdrawal in the Locus Ceruleus and Ventral Tegmental AreaThe Journal of Neuroscience, 2005
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamideBritish Journal of Pharmacology, 2001
- Functional Dissociation of μ Opioid Receptor Signaling and EndocytosisNeuron, 1999